Company: HROW
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022980
Chunk: 82

Company: HARROW, INC.
Filing Date: 2025-08-11
Form: 10-Q
Item: Item 2
Chunk 82
---
 manufacturers, and otherwise fund
our operations. We may also use our resources to conduct clinical trials or other studies in support of our formulations or any drug
candidate for which we pursue FDA approval, to pursue additional development programs or to explore other development opportunities.

Net
Cash Flow

The
following provides detailed information about our net cash flows for the six months ended June 30, 2025 and 2024:

    For the Six Months Ended June 30, 

    2025  
    2024 
  
    Net cash provided by (used in): 

    Operating activities 
    $18,865,000  
    $(7,374,000)
  
    Investing activities 
     (505,000) 
     4,993,000 
  
    Financing activities 
     (12,644,000) 
     (736,000)
  
    Net change in cash and cash equivalents 
     5,716,000  
     (3,117,000)
  
    Cash and cash equivalents at beginning of the period 
     47,247,000  
     74,085,000 
  
    Cash and cash equivalents at end of the period 
    $52,963,000  
    $70,968,000 

34

Operating
Activities

Net
cash provided by (used in) operating activities during the six months ended June 30, 2025 was $18,865,000 compared to $(7,374,000) during
the same period in the prior year. The increase in net cash provided by operating activities between the periods was mainly attributed
to a decrease of $37,211,000 in accounts receivable as a result of collections during the six months ended June 30, 2025, compared to
an increase in accounts receivable of $15,631,000 during the same period in 2024.

Investing
Activities

Net
cash (used in) provided by investing activities during the six months ended June 30, 2025 was $(505,000) compared to $4,993,000 during
the same period in the prior year. Cash used in investing activities in 2025 was primarily related to equipment and software purchases.
Cash provided by investing activities in 2024 was primarily related to the sale of our investment position in Eton.

Financing
Activities

Net
cash used in financing activities during the six months ended June 30,